67 related articles for article (PubMed ID: 25625229)
1. Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells.
Li X; Xu L; Li H; Zhao L; Luo Y; Zhu Z; Liu Y; Qu X
Mol Med Rep; 2015 Jun; 11(6):4547-54. PubMed ID: 25625229
[TBL] [Abstract][Full Text] [Related]
2. Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple‑negative breast cancer cell lines.
Gurdal H; Tuglu MM; Bostanabad SY; Dalkiliç B
Int J Oncol; 2019 Apr; 54(4):1345-1356. PubMed ID: 30720056
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
Knowlden JM; Hutcheson IR; Barrow D; Gee JM; Nicholson RI
Endocrinology; 2005 Nov; 146(11):4609-18. PubMed ID: 16037379
[TBL] [Abstract][Full Text] [Related]
4. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.
Kneissl J; Keller S; Lorber T; Heindl S; Keller G; Drexler I; Hapfelmeier A; Höfler H; Luber B
Int J Oncol; 2012 Aug; 41(2):733-44. PubMed ID: 22614881
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
6. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab.
Iyer G; Price J; Bourgeois S; Armstrong E; Huang S; Harari PM
BMC Cancer; 2016 Oct; 16(1):773. PubMed ID: 27716204
[TBL] [Abstract][Full Text] [Related]
8. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.
Song N; Liu S; Zhang J; Liu J; Xu L; Liu Y; Qu X
Int J Mol Sci; 2014 Apr; 15(4):5838-51. PubMed ID: 24714091
[TBL] [Abstract][Full Text] [Related]
10. Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.
Gao S; Bajrami I; Verrill C; Kigozi A; Ouaret D; Aleksic T; Asher R; Han C; Allen P; Bailey D; Feller S; Kashima T; Athanasou N; Blay JY; Schmitz S; Machiels JP; Upile N; Jones TM; Thalmann G; Ashraf SQ; Wilding JL; Bodmer WF; Middleton MR; Ashworth A; Lord CJ; Macaulay VM
Cancer Res; 2014 Oct; 74(20):5866-77. PubMed ID: 25168481
[TBL] [Abstract][Full Text] [Related]
11. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
[TBL] [Abstract][Full Text] [Related]
13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
14. Activation of insulin-like growth factor type-1 receptor is required for H2O2-induced PKB phosphorylation in vascular smooth muscle cells.
Azar ZM; Mehdi MZ; Srivastava AK
Can J Physiol Pharmacol; 2006 Jul; 84(7):777-86. PubMed ID: 16998541
[TBL] [Abstract][Full Text] [Related]
15. Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells.
Yu P; Fan Y; Qu X; Zhang J; Song N; Liu J; Liu Y
J BUON; 2016; 21(4):867-873. PubMed ID: 27685907
[TBL] [Abstract][Full Text] [Related]
16. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
19. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
[TBL] [Abstract][Full Text] [Related]
20. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
